Literature DB >> 23344826

Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients.

Hadi Poormoghim1, Alireza Salek Moghadam, Maziar Moradi-Lakeh, Mehrzad Jafarzadeh, Behnam Asadifar, Mohsen Ghelman, Elham Andalib.   

Abstract

To evaluate demographic, clinical and laboratory features associated with scleroderma-specific auto-antibodies. Sera of 100 patients with systemic sclerosis (SSc) were analyzed by an indirect immunofluorescence technique with HEp-2 cells as a substrate. Specific ANA such as anti-centromere antibodies (ACA), anti-topoisomerase (TOPO), anti-RNA polymerase III (Pol 3), anti-U3-RNP (U3-RNP), anti-Th/To (Th/To) and anti-PM/Scl (PM/Scl) were detected by line immunoassay and anti-U1-RNP (U1-RNP) by ELISA. Frequency of clinical features associated with a specific antibody group was reported cumulatively over the follow-up period. Frequency of specific clinical features was compared across the two disease subtype including limited cutaneous (lcSSc) or diffuse cutaneous (dcSSc) as well as the auto-antibody groups. Ninety-four percent of patients were ANA positive with significant higher skin score, Raynauds and digital ulcer/gangrene. Anti-TOPO was detected in 71% of all patients, in 90.5% of dcSSC and in 65.8% of lcSSc. Anti-TOPO was significantly associated with dcSSc, higher skin score, digital ulcer/gangrene, pulmonary fibrosis, DLCO <70%. U1-RNP antibody was associated with lower fibrosis in lung. ACA was positive in 7% of patients and exclusively in those with lcSSc. We did not find association between gender and presence of auto-antibodies. Anti-TOPO antibody had a high prevalence in contrast to low prevalence of ACA antibody. There were no differences in clinical subtypes of the disease in patients with positive anti-TOPO and positive ACA. Differences in prevalence of auto-antibodies are suggestive of further genetic study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23344826     DOI: 10.1007/s00296-013-2668-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  36 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

Review 2.  Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients.

Authors:  Clodoveo Ferri; Gabriele Valentini; Franco Cozzi; Marco Sebastiani; Claudio Michelassi; Giovanni La Montagna; Arianna Bullo; Massimiliano Cazzato; Enrico Tirri; Franca Storino; Dilia Giuggioli; Giovanna Cuomo; Mara Rosada; Stefano Bombardieri; Silvano Todesco; Giuseppe Tirri
Journal:  Medicine (Baltimore)       Date:  2002-03       Impact factor: 1.889

3.  Anti-fibrillarin antibodies in systemic sclerosis.

Authors:  V J Tormey; C C Bunn; C P Denton; C M Black
Journal:  Rheumatology (Oxford)       Date:  2001-10       Impact factor: 7.580

4.  Autoantibody detection using indirect immunofluorescence on HEp-2 cells.

Authors:  Ulrich Sack; Karsten Conrad; Elena Csernok; Ingrid Frank; Falk Hiepe; Thorsten Krieger; Arno Kromminga; Philipp von Landenberg; Gerald Messer; Torsten Witte; Rudolf Mierau
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

5.  Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay.

Authors:  Takashi Satoh; Osamu Ishikawa; Hironobu Ihn; Hirahito Endo; Yasushi Kawaguchi; Tetsuo Sasaki; Daisuke Goto; Kazuo Takahashi; Hiroki Takahashi; Yoshikata Misaki; Tsuneyo Mimori; Yoshinao Muro; Norihito Yazawa; Shinichi Sato; Kazuhiko Takehara; Masataka Kuwana
Journal:  Rheumatology (Oxford)       Date:  2009-10-05       Impact factor: 7.580

6.  Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis.

Authors:  C C Bunn; C P Denton; X Shi-Wen; C Knight; C M Black
Journal:  Br J Rheumatol       Date:  1998-01

7.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

Authors:  V D Steen; D L Powell; T A Medsger
Journal:  Arthritis Rheum       Date:  1988-02

8.  Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases.

Authors:  M Kuwana; K Kimura; M Hirakata; Y Kawakami; Y Ikeda
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

Review 9.  Scleroderma epidemiology.

Authors:  Maureen D Mayes
Journal:  Rheum Dis Clin North Am       Date:  2003-05       Impact factor: 2.670

10.  Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.

Authors:  A M Stupi; V D Steen; G R Owens; E L Barnes; G P Rodnan; T A Medsger
Journal:  Arthritis Rheum       Date:  1986-04
View more
  8 in total

1.  Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers.

Authors:  Yannick Allanore; Farhad Gharibdoost; Ahmad Reza Jamshidi; Ali Javinani; Jérôme Avouac; Elnaz Rastkar; Sadid Hooshmandi; Hoda Kavosi
Journal:  J Scleroderma Relat Disord       Date:  2018-11-20

2.  Prevalence and clinical associations with primary hypogonadism in male systemic sclerosis.

Authors:  Sapol Thepwiwatjit; Suranut Charoensri; Wichien Sirithanaphol; Ajanee Mahakkanukrauh; Siraphop Suwannaroj; Chingching Foocharoen
Journal:  J Scleroderma Relat Disord       Date:  2022-07-24

Review 3.  Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.

Authors:  Minoru Satoh; Angela Ceribelli; Tomoko Hasegawa; Shin Tanaka
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 10.817

4.  Association of Musculoskeletal and Radiological Features with Clinical and Serological Findings in Systemic Sclerosis: A Single-Centre Registry Study.

Authors:  Nasrin Azarbani; Ali Javadzadeh; Iman Mohseni; Arash Jalali; Elham Andalib; Hadi Poormoghim
Journal:  Mediterr J Rheumatol       Date:  2020-09-30

5.  Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study.

Authors:  Hadi Poormoghim; Nader Rezaei; Zeinab Sheidaie; Ali Reza Almasi; Maziar Moradi-Lakeh; Simin Almasi; Elham Andalib
Journal:  Rheumatol Int       Date:  2014-05-07       Impact factor: 2.631

6.  Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran.

Authors:  Hadi Poormoghim; Elham Andalib; Arash Jalali; Afshin Ghaderi; Ali Ghorbannia; Nazanin Mojtabavi
Journal:  Rheumatol Int       Date:  2016-04-09       Impact factor: 2.631

7.  Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition.

Authors:  Y A Suliman; C Bruni; S R Johnson; E Praino; M Alemam; N Borazan; L Cometi; B Meyers; D Khanna; Y Allanore; M Baron; T Krieg; A Herrick; A Afonso; O Distler; S Kafaja; C P Denton; M Matucci-Cerinic; D E Furst
Journal:  J Scleroderma Relat Disord       Date:  2017-05-19

8.  Characteristics of patients with systemic sclerosis living in Qatar.

Authors:  Fiaz Alam; Hani Malallah Abdulaziz; Irfan Ul Haq; Salah Mohamed Mahdy; Abdul Rahim Mohammed Siam; Prem Chandra; Samar Al Emadi
Journal:  Qatar Med J       Date:  2019-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.